

# David Taeb

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2586503/david-taieb-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126  
papers

3,042  
citations

30  
h-index

51  
g-index

144  
ext. papers

4,011  
ext. citations

6.7  
avg, IF

5.47  
L-index

#	Paper	IF	Citations
126	Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma.. <i>European Journal of Cancer</i> , <b>2022</b> , 169, 32-41	7.5	0
125	Familial hypocalciuric hypercalcemia: the challenge of diagnosis. <i>Endocrine</i> , <b>2021</b> , 1	4	0
124	High-Specific-Activity-I-MIBG versus Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2989-2995	12.9	8
123	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. <i>European Journal of Cancer</i> , <b>2021</b> , 146, 56-73	7.5	32
122	Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 625312	5.7	5
121	Imaging of Small Intestine Neuroendocrine Neoplasms: Is SSTR PET the Holy Grail?. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 1347-1348	8.9	1
120	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. <i>Nature Reviews Endocrinology</i> , <b>2021</b> , 17, 435-444	15.2	12
119	Novel Germline SUCLG2 Mutations in Patients With Pheochromocytoma and Paraganglioma. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, A168-A169	0.4	78
118	Personalized management of pheochromocytoma and paraganglioma. <i>Endocrine Reviews</i> , <b>2021</b> ,	27.2	18
117	Primary Hyperparathyroidism: Defining the Appropriate Preoperative Imaging Algorithm. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 3S-12S	8.9	3
116	Oncogenic osteomalacia related to an intramuscular mesenchymal tumor of the scalene muscles. <i>Kidney International</i> , <b>2021</b> , 100, 245	9.9	
115	Pheochromocytoma surgery without systematic preoperative pharmacological preparation: insights from a referral tertiary center experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2021</b> , 35, 728-735	5.2	8
114	Intraindividual comparison of F-FDOPA and Ga-DOTATOC PET/CT detection rate for metastatic assessment in patients with ileal neuroendocrine tumours. <i>Clinical Endocrinology</i> , <b>2021</b> , 94, 66-73	3.4	8
113	Risk stratification of adrenal masses by [ F]FDG PET/CT: Changing tactics. <i>Clinical Endocrinology</i> , <b>2021</b> , 94, 133-140	3.4	3
112	Positron Emission Tomography Imaging in Medullary Thyroid Carcinoma: Time for Reappraisal?. <i>Thyroid</i> , <b>2021</b> , 31, 151-155	6.2	10
111	Phaeochromocytoma and pregnancy: looking towards better outcomes, less fear, and valuable recommendations. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 2-3	18.1	2
110	PET in medullary thyroid carcinoma <b>2021</b> ,		

109 18F-FDOPA PET/CT for Treatment Response Assessment **2021**, 471-479

108 A Bright Future for Nuclear Endocrinology. *Journal of Nuclear Medicine*, **2021**, 62, 1S-2S 8.9 1

107 A Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses. *Journal of Nuclear Medicine*, **2021**, 62, 26S-33S 8.9 3

106 Values of Ga-DOTATOC and Carbidopa-assisted F-DOPA PET/CT for insulinoma localization. *Journal of Nuclear Medicine*, **2021**, 8.9 2

105 Sporadic Primary Pheochromocytoma: A Prospective Intra-Individual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using Ga-DOTATATE, FDG, F-FDOPA, and F-FDA). *American Journal of Roentgenology*, **2021**, 5.4 2

104 Predicting risk factors of postoperative hypocalcemia after total thyroidectomy: is safe discharge without supplementation possible? A large cohort study. *Langenbeck's Archives of Surgery*, **2021**, 406, 2425-2431 3.4 2

103 Germline SUCLG2 Variants in Patients with Pheochromocytoma and Paraganglioma. *Journal of the National Cancer Institute*, **2021**, 9.7 4

102 Variants and Pitfalls of PET/CT in Neuroendocrine Tumors. *Seminars in Nuclear Medicine*, **2021**, 51, 519-528 3.4 4

101 A long noncoding RNA-microRNA expression signature predicts metastatic signature in pheochromocytomas and paragangliomas. *Endocrine*, **2021**, 1 4 0

100 Quantitative biomarkers allow the diagnosis of head and neck paraganglioma on multiparametric MRI. *European Journal of Radiology*, **2021**, 143, 109911 4.7 0

99 The Global Reading Room: Nuclear Medicine Imaging of Suspected Paraganglioma. *American Journal of Roentgenology*, **2021**, 217, 1008-1009 5.4 0

98 MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives. *Endocrine*, **2020**, 69, 496-503 4 9

97 Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. *Metabolism: Clinical and Experimental*, **2020**, 110, 154297 12.7 3

96 Therapeutic Targeting of -Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid. *Clinical Cancer Research*, **2020**, 26, 3868-3880 12.9 12

95 Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. *Journal of Hypertension*, **2020**, 38, 1443-1456 1.9 62

94 Salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma: Long-term study. *Head and Neck*, **2020**, 42, 3133-3140 4.2 2

93 Comprehensive review of evaluation and management of cardiac paragangliomas. *Heart*, **2020**, 106, 1203-1210 3.1 2105

92 Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. *Gland Surgery*, **2020**, 9, 105-123<sup>2.2</sup> 21

91	Prognostic and predictive value of nuclear imaging in endocrine oncology. <i>Endocrine</i> , <b>2020</b> , 67, 9-19	4	4
90	Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	8
89	Catecholamine physiology and its implications in patients with COVID-19. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 978-986	18.1	19
88	An Uncommon Sinonasal Metastasis. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , <b>2020</b> , 146, 868-870	3.9	
87	Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 2326-2335	7.5	10
86	Genetic Determinants of Pheochromocytoma and Paraganglioma Imaging Phenotypes. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 643-645	8.9	4
85	Tumor multifocality with vagus nerve involvement as a phenotypic marker of SDHD mutation in patients with head and neck paragangliomas: A F-FDOPA PET/CT study. <i>Head and Neck</i> , <b>2019</b> , 41, 1565-1571	4.2	1
84	Exploring the link between tumour metabolism and succinate dehydrogenase deficiency: A F-FDOPA PET/CT study in head and neck paragangliomas. <i>Clinical Endocrinology</i> , <b>2019</b> , 91, 879-884	3.4	2
83	Limited role of carbidopa-assisted F-FDOPA PET/CT in patients with sporadic non-functional gastroduodenal neuroendocrine neoplasms. <i>Annals of Nuclear Medicine</i> , <b>2019</b> , 33, 697-707	2.5	2
82	The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40. <i>Cancers</i> , <b>2019</b> , 11,	6.6	11
81	Clinical, Diagnostic, and Treatment Characteristics of -Related Metastatic Pheochromocytoma and Paraganglioma. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 53	5.3	24
80	Thyroid cancer recurrence in the HiLo trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 252	18.1	
79	Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod). <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 1020-1028	5.6	0
78	Value of I/Tc-sestamibi parathyroid scintigraphy with subtraction SPECT/CT in primary hyperparathyroidism for directing minimally invasive parathyroidectomy. <i>American Journal of Surgery</i> , <b>2019</b> , 217, 108-113	2.7	9
77	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 2112-2137	8.8	113
76	Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. <i>Endocrine-Related Cancer</i> , <b>2019</b> , 26, R627-R652	5.7	39
75	Early F-FDOPA PET/CT imaging after carbidopa premedication as a valuable diagnostic option in patients with insulinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 686-695	8.8	12
74	Diagnostic Investigation of Lesions Associated with Succinate Dehydrogenase Defects. <i>Hormone and Metabolic Research</i> , <b>2019</b> , 51, 414-418	3.1	3

73	18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 1574-1582	5.6	17
72	Targeting NAD/PARP DNA Repair Pathway as a Novel Therapeutic Approach to -Mutated Cluster I Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3423-3432	12.9	38
71	Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. <i>Cell and Tissue Research</i> , <b>2018</b> , 372, 393-401	4.2	23
70	Characterization of adrenocortical tumors by F-FDG PET/CT: Does steroid hormone hypersecretion status modify the uptake pattern?. <i>Surgical Oncology</i> , <b>2018</b> , 27, 231-235	2.5	3
69	Quantitative F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 278-282	8.8	20
68	Radioactive iodine ablation in low-risk thyroid cancer. <i>Lancet Diabetes and Endocrinology</i> , <b>2018</b> , 6, 686	18.1	4
67	Delivering PET imaging results to cancer patients: steps for handling ethical issues. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 2240-2241	8.8	4
66	Superiority of Ga-DOTATATE over F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 787-797	8.8	38
65	A new methodology to derive 3D kinetic parametric FDG PET images based on a mathematical approach integrating an error model of measurement. <i>EJNMMI Research</i> , <b>2018</b> , 8, 99	3.6	0
64	RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective. <i>Cancers</i> , <b>2018</b> , 10,	6.6	5
63	Psychological impact of von Hippel-Lindau genetic screening in patients with a previous history of hemangioblastoma of the central nervous system. <i>Journal of Psychosocial Oncology</i> , <b>2018</b> , 36, 624-634	2.8	1
62	Prospective evaluation of Ga-DOTATATE PET/CT in limited disease neuroendocrine tumours and/or elevated serum neuroendocrine biomarkers. <i>Clinical Endocrinology</i> , <b>2018</b> , 89, 155-163	3.4	9
61	Head-to-head comparison between F-FDOPA PET/CT and MR/CT angiography in clinically recurrent head and neck paragangliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 979-987	8.8	10
60	Implications of SDHB genetic testing in patients with sporadic pheochromocytoma. <i>Langenbeck's Archives of Surgery</i> , <b>2017</b> , 402, 787-798	3.4	2
59	Utility of I-124 PET/CT in identifying radioiodine avid lesions in differentiated thyroid cancer: a systematic review and meta-analysis. <i>Clinical Endocrinology</i> , <b>2017</b> , 86, 645-651	3.4	28
58	Paraganglioma of the organ of Zuckerkandl associated with a somatic $\beta$ mutation: A case report. <i>Oncology Letters</i> , <b>2017</b> , 13, 1083-1086	2.6	2
57	Persistent and recurrent hyperparathyroidism. <i>Updates in Surgery</i> , <b>2017</b> , 69, 161-169	2.9	35
56	Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 2465-2472	5.6	44

55	F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma: relation to genotype and amino acid transport system L. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 812-821	8.8	13
54	The Evolving Role of Succinate in Tumor Metabolism: An F-FDG-Based Study. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1749-1755	8.9	22
53	Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery. <i>Annales D'Endocrinologie</i> , <b>2017</b> , 78, 162-175	1.7	23
52	Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1236-1242	8.9	24
51	PET Scans With 18F-Fluorodeoxyglucose to Diagnose Adrenal Tumors-Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 1614-1615	27.4	2
50	HIF-2alpha: Achilles Heel of pseudohypoxic subtype paraganglioma and other related conditions. <i>European Journal of Cancer</i> , <b>2017</b> , 86, 1-4	7.5	13
49	New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma. <i>Trends in Endocrinology and Metabolism</i> , <b>2017</b> , 28, 807-817	8.8	22
48	New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. <i>Endocrine Reviews</i> , <b>2017</b> , 38, 489-515	27.2	151
47	Recent advances in the imaging of pheochromocytomas and paragangliomas. <i>International Journal of Endocrine Oncology</i> , <b>2017</b> , 4, 137-144	0.3	
46	A Large Adrenal Tumor With Marked 18F-Fluorodeoxyglucose Uptake. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 84-85	27.4	
45	Pathological and Genetic Characterization of Bilateral Adrenomedullary Hyperplasia in a Patient with Germline MAX Mutation. <i>Endocrine Pathology</i> , <b>2017</b> , 28, 302-307	4.2	16
44	High-resolution magic angle spinning (1)H nuclear magnetic resonance spectroscopy metabolomics of hyperfunctioning parathyroid glands. <i>Surgery</i> , <b>2016</b> , 160, 384-94	3.6	9
43	Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 1949-1956	8.9	89
42	Quality of life, clinical outcomes and safety of early prophylactic levothyroxine administration in patients with GravesHyperthyroidism undergoing radioiodine therapy: a randomized controlled study. <i>European Journal of Endocrinology</i> , <b>2016</b> , 174, 491-502	6.5	16
41	PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 1784-91	8.8	106
40	Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas. <i>Journal of Neuro-Oncology</i> , <b>2016</b> , 126, 473-81	4.8	15
39	In vivo detection of catecholamines by magnetic resonance spectroscopy: A potential specific biomarker for the diagnosis of pheochromocytoma. <i>Surgery</i> , <b>2016</b> , 159, 1231-3	3.6	9
38	Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 1248-57	8.8	80

37	(18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 1027-33	8.8	33
36	<b>68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. <i>Journal of Nuclear Medicine</i>, <b>2016</b>, 57, 186-91</b>	8.9	120
35	Determination of the unmetabolised (18)F-FDG fraction by using an extension of simplified kinetic analysis method: clinical evaluation in paragangliomas. <i>Medical and Biological Engineering and Computing</i> , <b>2016</b> , 54, 103-11	3.1	9
34	An alternative parameter for early forecasting clinical response in NSCLC patients during radiotherapy: proof of concept study. <i>British Journal of Radiology</i> , <b>2016</b> , 89, 20160061	3.4	2
33	(18)F-DOPA: the versatile radiopharmaceutical. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 1187-9	8.8	8
32	Endocrine tumors associated with the vagus nerve. <i>Endocrine-Related Cancer</i> , <b>2016</b> , 23, R371-9	5.7	6
31	Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. <i>Endocrine-Related Cancer</i> , <b>2016</b> , 23, 899-908	5.7	49
30	Carbidopa-assisted F-fluorodihydroxyphenylalanine PET/CT for the localization and staging of non-functioning neuroendocrine pancreatic tumors. <i>Annals of Nuclear Medicine</i> , <b>2016</b> , 30, 659-668	2.5	11
29	Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 1144-55	8.8	26
28	Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics. <i>Endocrine-Related Cancer</i> , <b>2015</b> , 22, M1-8	5.7	26
27	The role of radionuclide imaging in the surgical management of primary hyperparathyroidism. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 737-44	8.9	62
26	Preoperative imaging for focused parathyroidectomy: making a good strategy even better. <i>European Journal of Endocrinology</i> , <b>2015</b> , 172, 519-26	6.5	35
25	<b>Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i>, <b>2015</b>, 21, 3888-95</b>	12.9	175
24	<b>18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study. <i>Journal of Nuclear Medicine</i>, <b>2015</b>, 56, 1849-54</b>	8.9	3
23	PET imaging in ectopic Cushing syndrome: a systematic review. <i>Endocrine</i> , <b>2015</b> , 50, 297-305	4	28
22	Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors. <i>PET Clinics</i> , <b>2015</b> , 10, 477-86	2.2	10
21	15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , <b>2015</b> , 22, T135-45	5.7	65
20	Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications. <i>Neoplasia</i> , <b>2015</b> , 17, 55-65	6.4	49

19	18F-FDOPA PET/CT imaging of insulinoma revisited. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 409-18	8.8	46
18	Imaging secondary hyperparathyroidism. <i>American Journal of Roentgenology</i> , <b>2014</b> , 203, W552	5.4	1
17	Renaissance of (18)F-FDG positron emission tomography in the imaging of pheochromocytoma/paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 2337-9	5.6	16
16	18F-FDG PET/CT as a predictor of hereditary head and neck paragangliomas. <i>European Journal of Clinical Investigation</i> , <b>2014</b> , 44, 325-332	4.6	24
15	Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions. <i>Clinical Endocrinology</i> , <b>2014</b> , 81, 317-28	3.4	21
14	Contemporary review of large adrenal tumors in a tertiary referral center. <i>Anticancer Research</i> , <b>2014</b> , 34, 2581-8	2.3	10
13	Topographic diagnosis: respective roles of morphological and functional imaging. <i>Annales D'Endocrinologie</i> , <b>2013</b> , 74, 185-90	1.7	3
12	Current and future trends in the anatomical and functional imaging of head and neck paragangliomas. <i>Seminars in Nuclear Medicine</i> , <b>2013</b> , 43, 462-73	5.4	15
11	Little cell neoplasms: a new differential diagnosis for 18F-FDOPA-avid thyroid nodules?. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 865-6	5.6	8
10	First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, E908-13	5.6	49
9	Parathyroid scintigraphy in renal hyperparathyroidism: the added diagnostic value of SPECT and SPECT/CT. <i>Clinical Nuclear Medicine</i> , <b>2013</b> , 38, 630-5	1.7	40
8	Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18)F-FDOPA PET: focus on missed lesions. <i>Clinical Endocrinology</i> , <b>2013</b> , 79, 170-7	3.4	43
7	EANM 2012 guidelines for radionuclide imaging of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39, 1977-95	8.8	193
6	Modern nuclear imaging for paragangliomas: beyond SPECT. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 264-74	7.4	74
5	First report of harlequin syndrome as the presenting feature of Carney Triad: a diagnostic and imaging challenge. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e168-71	2.2	7
4	Parathyroid scintigraphy: when, how, and why? A concise systematic review. <i>Clinical Nuclear Medicine</i> , <b>2012</b> , 37, 568-74	1.7	39
3	Health-related quality of life in thyroid cancer patients following radioiodine ablation. <i>Health and Quality of Life Outcomes</i> , <b>2011</b> , 9, 33	3	25
2	18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature?. <i>Journal of Nuclear Medicine</i> , <b>2009</b> , 50, 711-7	8.9	111



- 1 Tomoscintigraphy improves the determination of the embryologic origin of parathyroid adenomas, especially in apparently inferior glands: imaging features and surgical implications. *Journal of Nuclear Medicine Technology*, **2007**, 35, 135-9 1.1 18